Abstract
Corona virus disease (COVID-19) presents a serious threat to global health. A historical timeline of early molecular diagnostics from government alert (January 22) (D) was presented. After in silico analysis, Brazilian Army Institute of Biology (IBEx-RJ) tested samples in house using real-time reverse transcriptase polymerase chain reaction (RT-PCR) (fast mode) based on Centers for Disease Control and Prevention (CDC) recommendations. First cases from Brazil, Rio de Janeiro, IBEx, and diagnosis team were reported in D36, D44, D66, and D74 respectively. Therefore, after 1300 tests, we recommend N1/N2 primer sets (CDC) for preliminary and Charité protocol confirmation in case of positive results. Moreover, every professional should be tested before starting work, in addition to weekly tests for everyone involved.
Highlights
The tools used for the accurate diagnosis of these viral infections must have high sensitivity, specificity and preferably, affordability for the benefit of the entire population.[7]. The diagnosis of pathologies related to respiratory viruses in Brazil is mostly clinical, with low requisition of confirmatory laboratory tests, which results in the underreporting of these infections.[8]. Polymerase chain reaction (PCR) single plex tests have emerged in recent times, but they possess low resolvability due to the similarity in clinical signs and symptoms shared by many pathogens that cause respiratory viral infections
The new viral sequences were very different from all others, they were found to be closer to severe acute respiratory syndrome (SARS). [2] based on the limited information available regarding the primers of commercial respiratory panels, we concluded that it would not be possible to detect the new SARS-CoV-2 using these panels
Cycle conditions for SARS-Cov-2 real-time reverse transcriptase polymerase chain reaction (RT-PCR) detection based in Centers for Disease Control and Prevention (CDC) primers
Summary
The tools used for the accurate diagnosis of these viral infections must have high sensitivity, specificity and preferably, affordability for the benefit of the entire population.[7]. (2) based on the limited information available regarding the primers of commercial respiratory panels, we concluded that it would not be possible to detect the new SARS-CoV-2 using these panels.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
